Dalbavancin / Oritavancin / TelavancinAntibiotic family
Dalbavancin, oritavancin and telavancin are related lipoglycopeptide antibiotics. They share a broad chemical family but differ in persistence, indications and safety considerations.
Before comparing this entry. Three substance names share this source record. They require separate profiles before clinical comparison.
What is Dalbavancin / Oritavancin / Telavancin?
Dalbavancin, oritavancin and telavancin are lipoglycopeptide antibiotics. They share a chemical family but differ in persistence, treatment uses and safety considerations.
How it works
They disrupt processes required for the bacterial envelope and act against selected Gram-positive organisms. Their spectrum does not cover every cause of infection.
Effects studied
Treatment of bacterial skin infection
The retained comparative trial concerns dalbavancin in a defined skin-infection population. Its findings cannot automatically be assigned to oritavancin or telavancin. 1
Evidence: Agent-specific clinical trial
What does the evidence show?
The retained clinical paper concerns dalbavancin for bacterial skin infection. Its findings should not be assigned automatically to the other two medicines.
What they have in common
These antibiotics are related to glycopeptides such as vancomycin, with chemical modifications including lipid components. They act against particular Gram-positive bacteria by disrupting processes needed for the bacterial envelope. Their spectrum is relevant to some resistant infections, but does not make them universal antibiotics.
Why duration attracts attention
Dalbavancin and oritavancin can remain active for a long time, allowing less frequent administration in suitable settings. Telavancin has a different treatment schedule. Less frequent infusions can make treatment easier to arrange. A long-lasting medicine, however, cannot simply be removed once a dose has been given.
What the comparison establishes
A non-inferiority trial asks whether a treatment performs sufficiently close to an established comparator within a specified margin. It does not mean the new option is better for every infection. The dalbavancin paper retained here concerns a defined skin-infection population and treatment strategy. 1
Why the individual label matters
Kidney function, interacting medicines, infusion reactions and the suspected organism influence selection. Some risks and approved uses differ substantially across these three agents. Clinical decisions require the individual medicine’s current local product information and evidence that the organism is susceptible.
Safety & status
Kidney function, interacting medicines and infusion reactions affect selection. A long-persisting medicine cannot simply be withdrawn from the body after administration.
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Are these three interchangeable?
No. The individual medicine, organism, infection site and current product information determine the relevant use.
Does non-inferiority mean a drug is better?
No. It means the trial tested whether performance stayed within a prespecified margin of the comparator under the study conditions.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Dalbavancin / Oritavancin / Telavancin: paper 10.1056/NEJMoa1310480 Research reference · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.